Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [31] Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience
    Al-Shamsi, Humaid O.
    Fahmawi, Yazan
    Dahbour, Ibrahim
    Tabash, Aziz
    Rogers, Jane E.
    Mares, Jeannette Elizabeth
    Blum, Mariela A.
    Estrella, Jeannelyn
    Matamoros, Aurelio, Jr.
    Sagebiel, Tara
    Devine, Catherine E.
    Badgwell, Brian D.
    Lin, Quan D.
    Das, Prajnan
    Ajani, Jaffer A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (04) : 499 - 505
  • [32] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [33] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [34] Progression and treatment of HER2-positive breast cancer
    April Davoli
    Barbara A. Hocevar
    Thomas L. Brown
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 611 - 623
  • [35] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [36] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14) : 1273 - 1283
  • [37] Trastuzumab in HER2-Positive Metastatic Gastric Cancer Profile Report
    Croxtall, Jamie D.
    McKeage, Kate
    BIODRUGS, 2011, 25 (04) : 257 - 259
  • [38] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [39] HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective
    Swati Kulkarni
    David G. Hicks
    Annals of Surgical Oncology, 2008, 15 : 1677 - 1688
  • [40] Progression and treatment of HER2-positive breast cancer
    Davoli, April
    Hocevar, Barbara A.
    Brown, Thomas L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 611 - 623
12345